Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Autolus Therapeutics PLC Sponsored ADR (AUTL : NSDQ)

• Company Description    Autolus Therapeutics plc is a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies. The company's pipeline of product candidate involved in development for the treatment of haematological malignancies and solid tumours. Autolus Therapeutics plc is based in London, United Kingdom. Number of Employees: 399

• Price / Volume Information    Yesterday's Closing Price: $3.13 Daily Weekly Monthly 20 Day Moving Average: 1,049,707 shares Shares Outstanding: 173.07 (millions) Market Capitalization: $541.72 (millions) Beta: 1.56 52 Week High: $3.79 52 Week Low: $1.60 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 63.02% 56.85% 12 Week 57.29% 46.01% Year To Date 64.74% 49.85%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL THE MEDIAWORKS 191 WOOD LANE - LONDON,X0 W12 7FP GBR ph: 44-20-3829-6230 fax: - ir@autolus.com http://www.autolus.com

• General Corporate Information    Officers Christian Itin - Chief Executive Officer and Director John Johnson - Chairman of the Board of Directors Christopher Vann - Chief Operating Officer Andrew Oakley - Chief Financial Officer JosephAnderson - Director Peer Information Autolus Therapeutics PLC Sponsored ADR (CORR.) Autolus Therapeutics PLC Sponsored ADR (RSPI) Autolus Therapeutics PLC Sponsored ADR (CGXP) Autolus Therapeutics PLC Sponsored ADR (BGEN) Autolus Therapeutics PLC Sponsored ADR (GTBP) Autolus Therapeutics PLC Sponsored ADR (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 05280R100 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/23 Next Expected EPS Date: 08/03/23 Share - Related Items Shares Outstanding: 173.07 Most Recent Split Date: (:1) Beta: 1.56 Market Capitalization: $541.72 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.22 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.88 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/03/23

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.03 Price/Cash Flow: - Price / Sales: 243.25 EPS Growth vs. Year Ago Period: 43.90% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: 678.31% vs. Previous Quarter: -66.22% ROE 03/31/23 - -64.42 12/31/22 - -62.97 09/30/22 - -68.14 ROA 03/31/23 - -39.68 12/31/22 - -41.57 09/30/22 - -48.56 Current Ratio 03/31/23 - 9.94 12/31/22 - 9.18 09/30/22 - 5.47 Quick Ratio 03/31/23 - 9.94 12/31/22 - 9.18 09/30/22 - 5.47 Operating Margin 03/31/23 - - 12/31/22 - - 09/30/22 - - Net Margin 03/31/23 - - 12/31/22 - - 09/30/22 - - Pre-Tax Margin 03/31/23 - -2,328.35 12/31/22 - -2,723.35 09/30/22 - -6,969.80 Book Value 03/31/23 - 1.54 12/31/22 - 1.73 09/30/22 - 1.77 Inventory Turnover 03/31/23 - - 12/31/22 - - 09/30/22 - - Debt-to-Equity 03/31/23 - 0.00 12/31/22 - 0.00 09/30/22 - 0.07 Debt-to-Capital 03/31/23 - 0.00 12/31/22 - 0.00 09/30/22 - 6.56

Powered by Zacks Investment Research ©